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There is growing evidence supporting the idea that vascular
occlusions in pulmonary and systemic circulation are among
the most severe and common causes of poor outcome in
COVID-19 patients.1–7 These vascular events appear to be
mostly caused by local formation of thrombi, rather than by
venous thromboembolism,which likely formasaconsequence
of a thromboinflammatory process, triggered by viral infec-
tion-induced endothelial damage and cytokine storm, with
consequent activation of hemostasis leading to thrombus
formation and boosting inflammation further.8 Among the
several hemostasis players that are implicated in thromboin-
flammation, von Willebrand factor (VWF) has a leading
role.9–11VWFplays two important roles innormalhemostasis:
it carries factor VIII and mediates platelet-vessel wall and
platelet-to-platelet interaction, especially at high shear,
through its binding to the platelet membrane glycoprotein
(GP) Ib and GPIIb/IIIa.12 VWF is a multimeric protein that is
released into the circulation fromendothelial stores in a highly
thrombogenic form, characterized by the presence of ultra-
large multimers. Under normal circumstances, these ultra-
large multimers are cleaved by the protease ADAMTS-13 (a
disintegrin and metalloprotease with a thrombospondin type
1 motif, member 13) and, consequently, the high thromboge-
nicity of released VWF is reduced.12–14 Conditions that are
associatedwithcongenital or autoantibody-inducedADAMTS-
13 deficiency are characterized by increased incidence of
thrombotic complications, which may be very severe and
potentially fatal, as in thrombotic thrombocytopenic purpura
(TTP).15,16 Acquired deficiency of ADAMTS-13 is associated
also with systemic disorders, including severe inflammatory
diseases and sepsis.9,10,17 Considering that COVID-19 is a
severe inflammatory disease, it is plausible that it is associated
with acquired ADAMTS-13 deficiency and, hence, increased
thrombogenicity of VWF.
To test this hypothesis, we measured ADAMTS-13, VWF
levels, and other relevant tests in plasma from six patients
admitted to the intensive care unit of ASST Grande Ospedale
MetropolitanoNiguarda inMilano, Italy. Patients’ consent was
obtained on admission. All tests were performed by means of
commercial kits: in particular, VWF assays and ADAMTS-13
measurement were done by HemosIL AcuStar (Werfen,
Milano, Italy). Main clinical characteristics and laboratory
findings of the patients are reported in ►Table 1. Their
mean ( standard deviation) age was 62 5 years. Two
patients had cardiovascular risk factors (►Table 1). No throm-
botic events were diagnosed in 5 patients, while subclavian
and axillary veins thrombosis was detected in one; two
patients had bleeding events: rectorrhagia and a bleeding
complication after a tracheotomy procedure.
Factor VIII, D-dimer, fibrinogen, VWF:Ag (antigen), VWF:
RCo (ristocetin cofactor activity), and VWF:CB (collagen-
binding activity) were significantly increased in all patients,
confirming the results of a previous study (with the excep-
tion of VWF:CB, which had not been measured).18 These
results reflect a severe inflammatory state, as all the tested
proteins are known to be acute phase reactants and D-dimer
increases in inflammatory conditions. The original finding of
our study is that 5 of the 6 tested patients had plasma
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ADAMTS-13 levels lower than 45%, the lower limit of the
normal range: 3 of them had ADAMTS-13 levels around 30%,
possibly preventing the effective cleavage of VWFmultimers,
thus favoring the formation of local thrombi in the circula-
tion. Up to one-third of patientswith sepsis have been shown
to have ADAMTS-13 levels< 50%,17 while patients with
septic shock and ADAMTS-13 levels< 30% had increased
risk of mortality.19 Plasma levels of antibodies against
ADAMTS-13were normal in our patients, with the exception
of one, who displayed mild elevation of the antibody titer
(►Table 1). This observation reinforces the hypothesis that
low ADAMTS-13 levels in inflammation and sepsis are not
caused by autoimmunity, but by consumption by the large
amounts of VWF released in the circulation by endothelial
cells, and/or by cleavage by cell-derived proteases.17 It is
interesting to note that the VWF:RCo to VWF:Ag ratio was
Table 1 Clinical characteristics and main laboratory examinations of the six included patients
Reference
values
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age 63 65 54 59 65 68
Sex Female Male Female Male Male Male
Ethnicity Caucasian Caucasian Caucasian Caucasian Caucasian Hispanic
Hypertension No No No Yes Yes No
Diabetes No No No Yes No No
Prior cardiovascular disease No No No Yes No No
Prior antithrombotic treatments No No No No No No
ABO blood group 0 0 AB 0 A 0
Chronic kidney disease No No yes No No No
Clinical presentation
Fever Yes Yes Yes Yes Yes Yes
Cough Yes No Yes No Yes No
Dyspnea No Yes Yes No Yes No
Gastrointestinal disorders No No No Yes No No
Syncope No Yes No Yes No No
Disease severity status Critical Critical Critical Critical Critical Critical
Invasive mechanical ventilation Yes Yes Yes Yes Yes Yes
In-hospital death Yes No No No Yes No
Cerebrovascular events No No No No No No
Deep vein thrombosis No No No No No Yes
Pulmonary artery occlusion No No No No No No
Acute coronary syndrome No No No No No No
Vascular occlusion
in other districts
No No No No No No
Bleeding events Yes No No No No Yes
Peak creatinine, mg/dL 0.5–1.0 2.9 2.7 3.1 1.0 1.1 2.2
Peak blood urea nitrogen, mg/dL 18–48 249 226 220 109 53 140
FVIII, U/dL 51–147 279 316 308 229 240 259
VWF:Ag, U/dL 40–165 772 735 568 455 763 511
VWF:RCo, U/dL 41–151 451 496 470 339 496 448
VWF:CB, U/dL 45–174 612 683 502 397 623 485
ADAMTS-13, % 45–138 24 37 30 56 44 33
Anti-ADAMTS-13, U/mL < 12 < 12 < 12 < 12 Not tested < 12 18
IL-6, pg/mL < 7 7,152 Not tested Not tested 42 90 Not tested
C-reactive protein, mg/dL 0–0.5 24 45 45 30 31 19
Abbreviations: ADAMTS-13, a disintegrin andmetalloproteasewith a thrombospondin type 1motif, number 13; FVIII, factor VIII; IL-6, interleukin 6; VWF:Ag,
von Willebrand factor antigen; VWF:CB von Willebrand collagen-binding activity; VWF:RCo, von Willebrand factor ristocetin cofactor activity.
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slightly decreased in our COVID-19 patients, as it has already
been shown in another study,18 while the VWF:CB to VWF:
Ag ratio was close to unity. The correspondence between
VWF activity tests and immunological determinations of
VWF is probably not optimal when the amount of protein
present is extremely high; the better correspondence with
VWF:Ag that was displayed by VWF:CB, compared with
VWF:RCo, is likely a reflection of the greater sensitivity of
VWF:CB to very high molecular weight multimers,20 which
are likely increased in our patients with low ADAMTS-13
levels. Unfortunately, we could not measure VWF multimers
directly.
The mild–moderate decrease in plasma ADAMTS-13 lev-
els in COVID-19 patients is not expected to cause a throm-
botic microangiopathy of similar severity as that observed in
TTP, as testified also by the very mild reduction in platelet
count displayed byour patients. However, it could contribute
to the pathogenesis of thrombi. Indeed, the association of
low ADAMTS-13 plasma levels and thrombosis has already
been shown in previous studies: while the association with
thrombotic microangiopathies different from TTP, myocar-
dial infarction, and stroke is well established,21 that with
venous thromboembolism is less clear.22 This is in accor-
dance with the role of high molecular weight multimers of
VWF in supporting platelet-vessel wall interaction especially
at high shear rates that are encountered in the arterial
circulation.12,23 These considerations open the question of
what could be the most effective treatment of VWF-mediat-
ed thrombotic episodes in COVID-19. Heparin, whether
unfractionated or low molecular weight, is likely the best
therapeutic option to prevent venous thromboembolism
and, as a matter of fat, is recommended for thromboprophy-
laxis in all critically ill medical patients at risk.24 The
question for COVID-19, which is characterized by a
high degree of hypercoagulability,6,18 is whether doses of
heparin higher than those generally recommended are nec-
essary, which is being currently addressed by several ran-
domized clinical trials (NCT04372589, NCT04367831,
NCT04345848, NCT04366960). Heparin prophylaxis might
also limit the severity of disseminated intravascular coagu-
lation that is observed in COVID patients,6 albeit not very
frequently. In contrast, heparin is unlikely the ideal treat-
ment for microthrombosis in arterioles of the lungs and
other organs of COVID patients,8 for which treatment aimed
at restoring the balance between VWF and ADAMTS-13
(infusion of fresh-frozen plasma or recombinant ADAMTS-
13 concentrate), at inhibiting VWF–platelet interaction (in-
fusion of caplacizumab), or,more unspecifically, at inhibiting
platelet function, could have more promising results. Other
targets that play an important role in thromboinflammation
should also be considered in COVID-19.8
Limitations
The clinical relevance of the results of our study is limited by
its very small sample size. However, they are intended as
hypothesis-generatingonly, supporting a pathophysiological
concept that may foster further investigation of the throm-
boinflammatory process that characterizes COVID-19. A
study enrolling a much larger patient cohort would be
required to draw well-founded conclusions as to the poten-
tial pathogenic role of VWF/ADAMTS-13 unbalance in this
disorder.
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